Skip to main content

How is Tzield administered?

Medically reviewed by Carmen Pope, BPharm. Last updated on May 3, 2023.

Official answer

by Drugs.com

Tzield is given by intravenous infusion over a minimum of 30 minutes once daily for 14 consecutive days. Dosage is based on body surface area and increases as follows:

  • Day 1: 65 mcg/m2
  • Day 2: 125 mcg/m2
  • Day 3: 250 mcg/m2
  • Day 4: 500 mcg/m2
  • Days 5 through 14: 1,030 mcg/m2.

Tzield needs to be diluted before administration and patients should be premedicated with an NSAID or acetaminophen, an antihistamine, and/or an antiemetic, approximately one hour before administration of the infusion for at least the first 5 days of the infusion.

Only one dose should be administered per day. If a dose is missed, just resume the remaining doses on consecutive days to complete the 14-day treatment course.

References
  • Tzield Injection Prescribing Information. Updated 11/2022. Provention Bio, Inc. https://www.drugs.com/pro/tzield-injection.html
  • FDA Approves First Drug That Can Delay Onset of Type 1 Diabetes. November 17, 2022. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-can-delay-onset-type-1-diabetes

Read next

Tzield (teplizumab-mzwv) is an injectable medicine that is used to delay the onset of stage 3 Type 1 diabetes in people whose immune system has begun attacking their insulin-producing cells. Continue reading

Tzield is thought to work by binding to CD3 (a cell surface antigen present on T lymphocytes) to delay the onset of stage 3 type 1 diabetes in adults and children 8 and older with stage 2 type 1 diabetes. Tzield may also deactivate the immune cells that attack insulin-producing cells while increasing the proportion of cells that help moderate the immune response. Tzield is classified as an anti-CD3 monoclonal antibody. Continue reading

Tzield has been shown to delay the progression of Stage 2 type 1 diabetes to Stage 3 type 1 diabetes by 25 months (approximately 2 years) in a phase 3, randomized, double-blind clinical trial. In an extended follow-up of this trial (duration 923 days), the average time to diagnosis of stage 3 type 1 diabetes was 59.6 months for Tzield-treated patients compared with 27.1 months for patients given a placebo (a difference of 32.5 months). Continue reading

Related medical questions

Drug information

Related support groups

Medical Disclaimer